Efavirenz

[1]  A. Antinori,et al.  The Effect of HIV-1 Resistance Mutations after First-Line Virological Failure on the Possibility to Sequence Antiretroviral Drugs in Second-Line Regimens , 2006, Antiviral therapy.

[2]  S. Moreno,et al.  Antiretroviral therapy in AIDS patients with tuberculosis. , 2006, AIDS reviews.

[3]  S. Luchters,et al.  Efavirenz use during pregnancy and for women of child-bearing potential , 2006, AIDS research and therapy.

[4]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[5]  P. Harrigan,et al.  Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.

[6]  A. Vibhagool,et al.  Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results , 2006, AIDS.

[7]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[8]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[9]  Derick R. Peterson,et al.  Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults , 2004, Antimicrobial Agents and Chemotherapy.

[10]  B. Gazzard,et al.  Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 , 2004, PLoS medicine.

[11]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[12]  D. Podzamczer,et al.  Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[13]  G. Moyle.  Protease Inhibitor‐sparing Regimens: New Evidence Strengthens Position , 2003, Journal of acquired immune deficiency syndromes.

[14]  F. Maggiolo,et al.  Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients , 2002, HIV clinical trials.

[15]  F. Maggiolo,et al.  Once-A-Day Therapy for HIV Infection: A Controlled, Randomized Study in Antiretroviral-Naive HIV-1-Infected Patients , 2002, Antiviral therapy.

[16]  D. Back,et al.  The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. , 2001, British journal of clinical pharmacology.

[17]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[18]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[19]  B. Rewari,et al.  Antiretroviral Therapy for HIV Infection , 2007 .

[20]  F. Maggiolo,et al.  Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.